K-8669) with dalotuzumab (mk-0646) Fgf Dovitinib (TKI258)mTOR inhibitor and IGF-
K-8669) with dalotuzumab (mk-0646) Fgf Dovitinib (TKI258)mTOR inhibitor and IGF-1R mABNCTTKI inhibits Phase FGFR1?, VEGFR Phase / and PDGFRDovitinib (TKI258)Dovitinib (TKI258)Azd4547 AzdDovitinib monotherapy, four groups of MBC pts: (group Dovitinib…